DE69825292D1 - Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen - Google Patents
Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronenInfo
- Publication number
- DE69825292D1 DE69825292D1 DE69825292T DE69825292T DE69825292D1 DE 69825292 D1 DE69825292 D1 DE 69825292D1 DE 69825292 T DE69825292 T DE 69825292T DE 69825292 T DE69825292 T DE 69825292T DE 69825292 D1 DE69825292 D1 DE 69825292D1
- Authority
- DE
- Germany
- Prior art keywords
- inosine
- medicine
- producing
- axon growth
- neurones
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US921902 | 1997-09-02 | ||
US08/921,902 US6440455B1 (en) | 1997-09-02 | 1997-09-02 | Methods for modulating the axonal outgrowth of central nervous system neurons |
PCT/US1998/003001 WO1999011274A1 (en) | 1997-09-02 | 1998-02-20 | Use of purine nucleosides for modulating the axonal outgrowth of central nervous system neurons |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69825292D1 true DE69825292D1 (de) | 2004-09-02 |
DE69825292T2 DE69825292T2 (de) | 2005-05-25 |
Family
ID=25446158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69825292T Expired - Lifetime DE69825292T2 (de) | 1997-09-02 | 1998-02-20 | Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen |
Country Status (13)
Country | Link |
---|---|
US (8) | US6440455B1 (de) |
EP (2) | EP1466606A3 (de) |
JP (1) | JP4601816B2 (de) |
KR (1) | KR100564789B1 (de) |
CN (1) | CN1286632A (de) |
AT (1) | ATE271874T1 (de) |
AU (1) | AU748961B2 (de) |
CA (1) | CA2302156C (de) |
DE (1) | DE69825292T2 (de) |
HK (1) | HK1029916A1 (de) |
NZ (1) | NZ503073A (de) |
RU (1) | RU2212241C2 (de) |
WO (1) | WO1999011274A1 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440455B1 (en) | 1997-09-02 | 2002-08-27 | Children's Medical Center Corporation | Methods for modulating the axonal outgrowth of central nervous system neurons |
IL142896A0 (en) * | 1998-11-02 | 2002-04-21 | Elan Corp Plc | Multiparticulate modified release composition |
US20090297602A1 (en) * | 1998-11-02 | 2009-12-03 | Devane John G | Modified Release Loxoprofen Compositions |
US7582680B1 (en) | 1998-11-12 | 2009-09-01 | Purdue Research Foundation | Methods and compositions for treating mammalian spinal cord injuries |
US7172871B1 (en) * | 2000-09-07 | 2007-02-06 | Children's Medical Center Corporation | Methods and compositions for modulating axonal outgrowth of central nervous system neurons |
FR2814077A1 (fr) * | 2000-09-20 | 2002-03-22 | Inst Nat Sante Rech Med | Utilisation de modulateurs de recepteurs a l'adenosine pour reguler la fonction des netrines et/ou de leurs recepteurs |
WO2002051438A2 (en) | 2000-12-22 | 2002-07-04 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (rgm) and its modulators |
NZ543953A (en) * | 2001-04-24 | 2007-04-27 | Univ Chicago | Method and compositions for treating mammalian nerve tissue injuries |
US7147647B2 (en) * | 2002-04-26 | 2006-12-12 | Medtronic, Inc. | Sintered titanium tube for the management of spinal cord injury |
US20040106896A1 (en) * | 2002-11-29 | 2004-06-03 | The Regents Of The University Of California | System and method for forming a non-ablative cardiac conduction block |
US7813473B2 (en) * | 2002-07-23 | 2010-10-12 | General Electric Company | Method and apparatus for generating temporally interpolated projections |
US6904118B2 (en) | 2002-07-23 | 2005-06-07 | General Electric Company | Method and apparatus for generating a density map using dual-energy CT |
WO2004022039A2 (en) * | 2002-09-03 | 2004-03-18 | Neurological Technologies Inc. | Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system |
JP2006501936A (ja) * | 2002-10-04 | 2006-01-19 | エラン ファーマ インターナショナル,リミティド | 固体ナノ粒子活性薬剤のガンマ線照射 |
GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
JP2006517807A (ja) * | 2002-12-30 | 2006-08-03 | パーデュー・リサーチ・ファウンデーション | 中枢神経系の損傷の治療方法 |
JP2007501683A (ja) * | 2003-05-22 | 2007-02-01 | エラン ファーマ インターナショナル リミテッド | γ線照射によるナノ粒子活性物質分散体の滅菌法 |
GB0312844D0 (en) * | 2003-06-04 | 2003-07-09 | Paradigm Therapeutics Ltd | Use of compounds in medicine |
WO2005016359A1 (en) * | 2003-08-19 | 2005-02-24 | Neurological Technologies Inc. | Method of promoting remyelination |
US8912144B2 (en) * | 2003-12-16 | 2014-12-16 | Children's Medical Center Corporation | Method for treating stroke via administration of NEP1-40 and inosine |
US20080113016A1 (en) * | 2004-07-26 | 2008-05-15 | Gary Steven Firestein | Method for Prevention or Treatment of Inflammatory Disease |
US20060104969A1 (en) * | 2004-08-16 | 2006-05-18 | Massachusetts Institute Of Technology | Compositions and methods for enhancing structural and functional nervous system reorganization and recovery |
JP2008531721A (ja) * | 2005-03-03 | 2008-08-14 | エラン・ファルマ・インターナショナル・リミテッド | 複素環式アミド誘導体のナノ粒子状組成物 |
WO2006111348A1 (de) * | 2005-04-18 | 2006-10-26 | Abbott Gmbh & Co. Kg | Verwendung von heparin und heparinderivaten zur modulation des neuritenwachstum-kontrollierenden nogo-rezeptors |
EP1928905B1 (de) | 2005-09-30 | 2015-04-15 | AbbVie Deutschland GmbH & Co KG | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung |
CA2647770A1 (en) * | 2006-03-31 | 2007-10-11 | Adenobio N.V. | Compositions, methods, and kits using adenosine and inosine in combination for diagnosis and treatment |
JP2009543803A (ja) * | 2006-07-12 | 2009-12-10 | エラン・ファルマ・インターナショナル・リミテッド | モダフィニルのナノ粒子製剤 |
US20080140056A1 (en) * | 2006-12-06 | 2008-06-12 | Medtronic, Inc. | Method for delivering large molecules to the brain |
US20080270686A1 (en) * | 2007-04-26 | 2008-10-30 | Grannan Michael F | Methods and system to cache content on a vehicle |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
EP2259677A4 (de) * | 2008-02-29 | 2011-11-02 | Alseres Pharmaceuticals Inc | Systemische purinverabreichung zur modulation des axonalen wachstums des zentralnervensystems |
EP2502623B1 (de) | 2008-06-06 | 2016-04-06 | Children's Medical Center Corporation | Förderung der Neuritregeneration im Erwachsenen-ZNS durch Steuerung der Proteintranslation |
BR112012013734A2 (pt) | 2009-12-08 | 2017-01-10 | Abbott Gmbh & Co Kg | anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina. |
IL297229A (en) | 2012-01-27 | 2022-12-01 | Abbvie Inc | The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells |
US20140179741A1 (en) * | 2012-10-10 | 2014-06-26 | Massachusetts Institute Of Technology | Use of chelators of divalent cations to promote nerve regeneration |
WO2014096958A1 (en) * | 2012-11-02 | 2014-06-26 | Academisch Medisch Centrum | Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders |
RU2517117C2 (ru) * | 2012-11-26 | 2014-05-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Казанский ГМУ Минздравсоцразвития России) | Способ стимулирования регенерации нерва с помощью наноструктурированного матрикса и генетических конструкций |
MX2018002263A (es) * | 2015-08-26 | 2018-03-23 | Stagen Co Ltd | Potenciador de atp intracelular. |
WO2020140730A1 (zh) * | 2018-12-30 | 2020-07-09 | 广州君赫生物科技有限公司 | 硫鸟嘌呤在制备治疗adsl缺陷症药物中应用 |
EP3797764A1 (de) | 2019-09-27 | 2021-03-31 | Janusz Chupty Contissi | Pharmakologische zusammensetzung zur behandlung von dysfunktion des nervengewebes, insbesondere der viralen latenz, und die verwendung von substanzen der gruppe j05 atc zur behandlung von dysfunktion des nervengewebes, insbesondere der viralen latenz |
WO2021260740A1 (en) * | 2020-06-25 | 2021-12-30 | Celagenex Research (India) Pvt. Ltd. | Novel synergistic nutritional compositions for promoting axonal regeneration |
WO2023055531A1 (en) * | 2021-09-28 | 2023-04-06 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods for treating peripheral neuropathy |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3808027A (en) | 1972-03-29 | 1974-04-30 | Du Pont | Silica surfaced films |
US4341868A (en) * | 1978-08-18 | 1982-07-27 | Kyowa Hakko Kogyo Co., Ltd. | Method and test composition for the determination of the substrate for xanthine oxidase |
US4883666A (en) * | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
WO1988009335A1 (en) | 1987-05-26 | 1988-12-01 | Paul Gordon | Polymorphs of inosine and methods of making and using them |
US5250414A (en) * | 1988-11-04 | 1993-10-05 | Erziehungsdirektion Of The Canton Zurich | Diagnostic methods using neurite growth regulatory factors |
US5187162A (en) | 1989-09-15 | 1993-02-16 | Gensia Pharmaceuticals | Methods of treating neurodegenerative conditions |
AU643235B2 (en) * | 1989-09-15 | 1993-11-11 | Gensia Pharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
FR2692784B1 (fr) * | 1992-06-24 | 1995-06-30 | Pf Medicament | Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux. |
US5483130A (en) * | 1992-09-09 | 1996-01-09 | Axelerator, Inc. | Structure for accelerating heavy ions with uniformly spaced quadrupole focusing (USQF) |
US5422343A (en) * | 1992-12-21 | 1995-06-06 | Otsuka Pharmaceutical Factory, Inc. | Prophylactic and therapeutic composition for MRSA infection |
US5438130A (en) * | 1993-01-15 | 1995-08-01 | Cambridge Neuroscience, Inc. | Fucosylated guanosine disulfates as excitatory amino acid antagonists |
RU2063753C1 (ru) | 1993-04-22 | 1996-07-20 | Василий Владимирович Афанасьев | Способ лечения экстрапирамидного синдрома при остром отравлении галоперидолом |
CN1128951A (zh) * | 1993-08-13 | 1996-08-14 | 生化学工业株式会社 | 治疗神经元疾病的药物 |
US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
US5447939A (en) * | 1994-07-25 | 1995-09-05 | Glasky; Alvin J. | Carbon monoxide dependent guanylyl cyclase modifiers and methods of use |
US5931809A (en) | 1995-07-14 | 1999-08-03 | Depotech Corporation | Epidural administration of therapeutic compounds with sustained rate of release |
AU4808997A (en) * | 1996-09-30 | 1998-04-24 | Brigham And Women's Hospital | Methods and compounds for treatment of abnormal uterine bleeding |
US6440455B1 (en) * | 1997-09-02 | 2002-08-27 | Children's Medical Center Corporation | Methods for modulating the axonal outgrowth of central nervous system neurons |
US6855690B2 (en) * | 2000-06-01 | 2005-02-15 | Children's Medical Center Corporation | Methods and compositions for treating ocular disorders |
GB2379797A (en) * | 2001-09-15 | 2003-03-19 | Zarlink Semiconductor Ab | Surface Emitting Laser |
-
1997
- 1997-09-02 US US08/921,902 patent/US6440455B1/en not_active Expired - Fee Related
-
1998
- 1998-02-20 AU AU66568/98A patent/AU748961B2/en not_active Ceased
- 1998-02-20 EP EP04009962A patent/EP1466606A3/de not_active Withdrawn
- 1998-02-20 JP JP2000508376A patent/JP4601816B2/ja not_active Expired - Fee Related
- 1998-02-20 KR KR1020007002226A patent/KR100564789B1/ko not_active IP Right Cessation
- 1998-02-20 DE DE69825292T patent/DE69825292T2/de not_active Expired - Lifetime
- 1998-02-20 CA CA002302156A patent/CA2302156C/en not_active Expired - Fee Related
- 1998-02-20 NZ NZ503073A patent/NZ503073A/xx unknown
- 1998-02-20 WO PCT/US1998/003001 patent/WO1999011274A1/en not_active Application Discontinuation
- 1998-02-20 RU RU2000108443/14A patent/RU2212241C2/ru not_active IP Right Cessation
- 1998-02-20 CN CN98810807A patent/CN1286632A/zh active Pending
- 1998-02-20 EP EP98908565A patent/EP1009412B1/de not_active Expired - Lifetime
- 1998-02-20 AT AT98908565T patent/ATE271874T1/de not_active IP Right Cessation
-
2000
- 2000-12-19 HK HK00108201A patent/HK1029916A1/xx not_active IP Right Cessation
-
2001
- 2001-11-29 US US09/997,688 patent/US6551612B2/en not_active Expired - Lifetime
- 2001-11-29 US US09/997,687 patent/US20020055484A1/en not_active Abandoned
-
2002
- 2002-05-14 US US10/145,224 patent/US20020128223A1/en not_active Abandoned
- 2002-05-14 US US10/144,952 patent/US20020137721A1/en not_active Abandoned
-
2003
- 2003-03-10 US US10/385,031 patent/US20040014710A1/en not_active Abandoned
-
2005
- 2005-05-19 US US11/132,701 patent/US7338666B2/en not_active Expired - Fee Related
-
2007
- 2007-02-16 US US11/708,098 patent/US7935680B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20070213294A1 (en) | 2007-09-13 |
US20040014710A1 (en) | 2004-01-22 |
ATE271874T1 (de) | 2004-08-15 |
US20020137721A1 (en) | 2002-09-26 |
KR100564789B1 (ko) | 2006-03-28 |
RU2212241C2 (ru) | 2003-09-20 |
EP1466606A3 (de) | 2004-11-24 |
AU748961B2 (en) | 2002-06-13 |
CN1286632A (zh) | 2001-03-07 |
US20050277614A1 (en) | 2005-12-15 |
EP1009412B1 (de) | 2004-07-28 |
US7338666B2 (en) | 2008-03-04 |
JP2001516695A (ja) | 2001-10-02 |
CA2302156A1 (en) | 1999-03-11 |
HK1029916A1 (en) | 2001-04-20 |
WO1999011274A1 (en) | 1999-03-11 |
US7935680B2 (en) | 2011-05-03 |
US6551612B2 (en) | 2003-04-22 |
US20020128223A1 (en) | 2002-09-12 |
DE69825292T2 (de) | 2005-05-25 |
EP1009412A1 (de) | 2000-06-21 |
US20020055484A1 (en) | 2002-05-09 |
KR20010023578A (ko) | 2001-03-26 |
US6440455B1 (en) | 2002-08-27 |
AU6656898A (en) | 1999-03-22 |
NZ503073A (en) | 2002-11-26 |
JP4601816B2 (ja) | 2010-12-22 |
EP1466606A2 (de) | 2004-10-13 |
CA2302156C (en) | 2006-11-21 |
US20020042390A1 (en) | 2002-04-11 |
RU2000108443A (ru) | 2002-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69825292D1 (de) | Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen | |
DE3684190D1 (de) | Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. | |
ATE83659T1 (de) | Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus. | |
DE19675046I2 (de) | Pharmazeutische Verbindungen | |
DE69331605T2 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
HU0301601D0 (en) | Bis(n-substituted)-staurosporine derivatives, their use and pharmaceutical composition containing thereof | |
BG102202A (en) | Enantiomer and ipratropiumbromide with extended effect | |
IL104006A0 (en) | Azaheterocyclylmethyl-chromans,their preparation and pharmaceutical compositions containing them | |
ATE256475T1 (de) | Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten | |
HUT59313A (en) | Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions | |
WO1997003188A3 (de) | Verwendung von mp52 oder mp121 zur behandlung und prävention von erkrankungen des nervensystems | |
ATE191849T1 (de) | Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst | |
ATE307203T1 (de) | Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma | |
DE69200711D1 (de) | Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung. | |
ATE94764T1 (de) | Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung. | |
NO944339D0 (no) | Melatoninderivater for anvendelse ved behandling av sövnforstyrrelser | |
GR3019774T3 (en) | Piperidylmethyl substituted chroman derivatives as agents for the treatment of diseases of the central nervous system | |
PT656209E (pt) | Derivados de melatonina para uso no tratamento de perturbacoes de dessincronizacao | |
DE59304087D1 (de) | Placentaextrakt und Verfahren zu seiner Herstellung | |
EP0495998A4 (de) | ||
DE68901172D1 (de) | (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend. | |
DE69424415T2 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit | |
NO952912L (no) | En ny osteoblastisk proliferativ faktor | |
CA2154485A1 (en) | Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders | |
UA10259A (uk) | Протинабряковий лікарський препарат "нейрополіосм" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de | ||
8370 | Indication related to discontinuation of the patent is to be deleted | ||
8364 | No opposition during term of opposition |